24
March
2008
Zenda Technologies CEO Tapped For the Georgia Tech Technology Commercialization Services VentureLab Unit
Posted by
mgilstrapWP under:
Press .
Atlanta, Georgia, March 24th – Zenda Technologies, provider of innovative neuropsychological assessment solutions (http://www.zendatech.com/), today announced that CEO Lawrence Catchpole has been appointed to serve as a Fellow of the Georgia Tech VentureLab. VentureLab is a unit of Commercialization Services (CS), which evaluates and commercializes Georgia Tech intellectual property. Most research discoveries are suitable for licensing to existing corporations, with about 10 percent of discoveries judged to have the right stuff for forming a VentureLab startup.
Georgia Tech’s $400 million-plus annual research budget generates more than 300 invention disclosures each year.
VentureLab Fellows select particular discoveries that show promise as the basis for fast-growth startup companies. Then they provide those startups with support that includes help in securing seed funding, office/lab space and business and legal guidance. “Our VentureLab Fellows have hundreds of years of entrepreneurial experience among them,” said Stephen Fleming, director of Georgia Tech’s Commercialization Services, VentureLab’s parent organization. “By matching Georgia Tech researchers with proven entrepreneurs, we’re making a direct connection to the marketplace and building teams that can launch successful technology companies.”
“I’m extremely honored to have the opportunity to work with VentureLab,” said Lawrence Catchpole, CEO of Zenda Technologies a VentureLab Company. “I have deep passion for nurturing emerging technology, building successful companies around it, and for the Georgia Tech community.”Catchpole has more than 30 years of experience as a leader and entrepreneur in the technology industry. As chief strategy officer and founder of M1 Global, Catchpole was responsible for setting strategic business direction and technology vision, while raising $15 million and using innovative and successful development techniques. He was also founder and CTO of WebTone, which grew into a multi-channel financial services market company with 230 employees and $38 million in sales before being acquired by Fidelity National in 2003. He has also held senior positions at S1 Technologies and Dun & Bradstreet Software (formerly MSA). He holds a bachelor’s degree in applied biology with a minor in electrical engineering from Georgia Tech.
“The VentureLab Fellow program is a two-way street,” added Fleming, who is also Georgia Tech’s chief commercialization officer. “Although the Fellows are volunteers, they may encounter a company that’s a particularly good fit and go on to assume a leadership position.” This is the case with Catchpole and his position with Zenda Technologies. Zenda is the product of a new neuropsychological testing inventions, co-created by researchers at Georgia Tech and Emory University.
About VentureLab: Georgia Tech VentureLab (http://innovate.gatech.edu) provides comprehensive assistance to Georgia Tech faculty, research staff and graduate students who want to form startup companies to commercialize the technology innovations they have developed.
As a one-stop center for technology commercialization, VentureLab provides a clear pathway from laboratory innovation to the commercial market. VentureLab specialists help transform innovations into early-stage companies by assisting in business plan development, connecting the innovators with experienced entrepreneurs, locating sources of early-stage financing, and preparing the new companies for the business world. Graduates of the VentureLab program may apply for admission to the Advanced Technology Development Center (ATDC), which is also part of the Georgia Tech Enterprise Innovation Institute.
About Zenda TechnologiesZenda Technologies - www.zendatech.com - The purpose of Zenda Technologies is to deliver a novel, portable, immersive platform for rapid neuropsychological testing (ImTECH™). Our first test on the platform (DETECT) will screen for mild cognitive impairment (MCI) - symptomatic of early Alzheimer’s disease.
Leave a Reply
